---
title: "Dyne Therapeutics reports $791.9 million cash position as of September 30, 2025"
description: "Dyne Therapeutics Inc. reported a net loss of $108.0 million for Q3 2025, with cash and equivalents totaling $791.9 million as of September 30, 2025. The company anticipates these funds will support o"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/264500656.md"
published_at: "2025-11-05T21:27:54.000Z"
---

# Dyne Therapeutics reports $791.9 million cash position as of September 30, 2025

> Dyne Therapeutics Inc. reported a net loss of $108.0 million for Q3 2025, with cash and equivalents totaling $791.9 million as of September 30, 2025. The company anticipates these funds will support operations until Q3 2027. R&D expenses rose to $97.2 million, while general and administrative expenses increased to $16.7 million. Dyne is on track to report data from the DELIVER trial in December 2025, with potential U.S. accelerated approval submission in Q2 2026 for zeleciment rostudirsen, which received Breakthrough Therapy Designation from the FDA.

Dyne Therapeutics Inc. reported a net loss of $108.0 million, or $0.76 per basic and diluted share, for the third quarter ended September 30, 2025, compared to a net loss of $97.1 million, or $0.96 per basic and diluted share, for the same period in 2024. Research and development expenses were $97.2 million, up from $92.8 million in the prior year quarter. General and administrative expenses were $16.7 million, compared to $12.9 million a year earlier. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $791.9 million, with the company expecting these funds to support operations into the third quarter of 2027. Business developments included the company remaining on track to report topline data from the registrational expansion cohort of the DELIVER trial of zeleciment rostudirsen in December 2025, supporting a potential U.S. accelerated approval submission in the second quarter of 2026. The FDA granted Breakthrough Therapy Designation to zeleciment rostudirsen for DMD patients amenable to exon 51 skipping. U.S. sites were activated in the ACHIEVE trial of zeleciment basivarsen in DM1, with enrollment completion now expected in early second quarter of 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-266979), on November 05, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [DYN.US - Dyne Therapeutics](https://longbridge.com/en/quote/DYN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Dyne Therapeutics Chief Commercial Officer Johanna Friedl-Naderer Reports Sale of Common Shares | Johanna Friedl-Naderer, Chief Commercial Officer of Dyne Therapeutics Inc., has reported the sale of common shares of th | [Link](https://longbridge.com/en/news/268800538.md) |
| Dyne Therapeutics Announces Positive One-Year Clinical Data for DMD and DM1 Therapies | Dyne Therapeutics Inc. announced positive one-year clinical data for its therapies targeting DMD and DM1. The company re | [Link](https://longbridge.com/en/news/264498552.md) |
| Nonprofit models support strategic boldness to develop gene therapies for rare diseases | Généthon CEO Frédéric Revah emphasizes the importance of nonprofit funding models in developing gene therapies for rare  | [Link](https://longbridge.com/en/news/277062424.md) |
| BUZZ-Larimar jumps on FDA's 'breakthrough' tag for neurological disorder therapy | Shares of therapy developer Larimar Therapeuticsjump 32% to $3.71 premarketCo says the U.S. FDA granted a breakthrough d | [Link](https://longbridge.com/en/news/276742755.md) |
| enGene Maps BLA by End-2026, Targets 2027 Launch for Lead NMIBC Therapy at Oppenheimer Conference | enGene's CEO Ron Cooper presented the company's regulatory and clinical plans for its lead therapy, detalimogene vorapla | [Link](https://longbridge.com/en/news/277262258.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.